EIGR.Q Stock Overview A commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Eiger BioPharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Eiger BioPharmaceuticals Historical stock prices Current Share Price US$8.50 52 Week High US$16.00 52 Week Low US$1.10 Beta 2.78 1 Month Change -15.00% 3 Month Change -24.11% 1 Year Change -5.59% 3 Year Change -95.66% 5 Year Change -97.13% Change since IPO -98.22%
Recent News & Updates Eiger BioPharmaceuticals, Inc. Went Out of Business Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc. Aug 22
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc. Aug 06
Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million. Jul 11
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million. May 10
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index Apr 11 See more updates Eiger BioPharmaceuticals, Inc. Went Out of Business Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc. Aug 22
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc. Aug 06
Spruce Biosciences, Inc. (NasdaqGS:SPRB) completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million. Jul 11
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million. May 10
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index Apr 11 The Nasdaq Stock Market LLC Determines Eiger Biopharmaceuticals' Common Stock to be Delisted from Nasdaq Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy Apr 01
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues Apr 01 Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy Apr 01
Price target decreased by 67% to US$30.00 Mar 22
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024 Jan 25
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan Jan 19
The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26% Jan 04
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals Nov 26
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals Nov 25
Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding No Longer Satisfies the $10 Million Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Global Market Nov 14
New major risk - Negative shareholders equity Nov 11
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 11
New major risk - Market cap size Oct 28
Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Sep 13
No longer forecast to breakeven Aug 17
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 16
Eiger BioPharmaceuticals Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) Jul 30
New major risk - Share price stability Jul 02
Consensus EPS estimates upgraded to US$1.45 loss Jul 01 Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from Russell Small Cap Comp Value Index
No longer forecast to breakeven May 15
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Consensus EPS estimates upgraded to US$1.57 loss, revenue downgraded Mar 29
Consensus EPS estimates upgraded to US$1.07 loss, revenue downgraded Mar 24
No longer forecast to breakeven Mar 21
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 17
Eiger BioPharmaceuticals, Inc. Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19 Feb 09
Independent Chairman recently bought US$72k worth of stock Jan 27
Eiger BioPharmaceuticals, Inc. Announces Sriram Ryali to Resign as Chief Financial Officer, Effective January 20, 2023 Jan 10
Forecast to breakeven in 2025 Dec 31
Key Executive recently bought US$128k worth of stock Dec 29
RM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc Dec 20
Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22% Dec 20 Eiger BioPharmaceuticals, Inc. Announces CEO Changes
Price target decreased to US$9.25 Dec 09
Eiger BioPharmaceuticals, Inc. Announces Topline Primary Week 48 Data from Its Landmark Phase 3 D-LIVR study Dec 09
Forecast to breakeven in 2024 Nov 16
Pomerantz Law Firm Announces the Filing of a Class Action Against Eiger BioPharmaceuticals, Inc Nov 09
Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher Nov 09
Third quarter 2022 earnings: EPS misses analyst expectations Nov 05
Eiger BioPharmaceuticals, Inc. Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback Oct 06
Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt Oct 06
Eiger sheds ~20% on abandonment of EUA request for COVID therapy Oct 05
Eiger Biopharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application Sep 07
Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy Sep 06
Consensus forecasts updated Aug 11
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 05
Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst Jul 26
Eiger Biopharmaceuticals Inc. Announces European Commission (Ec) Has Granted Marketing Authorization for Zokinvy® (Lonafarnib Jul 21
European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy Jul 20
Eiger BioPharmaceuticals, Inc. Appoints Lisa Kelly-Croswell to Board of Directors Jul 19
Eiger BioPharmaceuticals, Inc. Announces Results from Multiple Presentations at the European Association for the Study of the Liver International Liver Congress 2022 Jun 29
Eiger Biopharmaceuticals, Inc. Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries Jun 14
Insufficient new directors Jun 01
Eiger Biopharmaceuticals, Inc. Receives Positive Chmp Opinion for Zokinvy as A Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies May 21
Consensus revenue estimates fall by 22% May 12
Insufficient new directors May 02
Price target increased to US$32.00 Apr 27
Eiger BioPharmaceuticals, Inc. Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program Apr 26
Eiger Biopharmaceuticals, Inc. Announces New Executive Appointments Apr 19 Shareholder Returns EIGR.Q US Biotechs US Market 7D 0% -0.2% 3.2% 1Y -5.6% -7.0% 24.2%
See full shareholder returns
Return vs Industry: EIGR.Q underperformed the US Biotechs industry which returned 21.7% over the past year.
Return vs Market: EIGR.Q underperformed the US Market which returned 33.4% over the past year.
Price Volatility Is EIGR.Q's price volatile compared to industry and market? EIGR.Q volatility EIGR.Q Average Weekly Movement 12.9% Biotechs Industry Average Movement 11.2% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: EIGR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: EIGR.Q's weekly volatility has decreased from 39% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
Show more Eiger BioPharmaceuticals, Inc. Fundamentals Summary How do Eiger BioPharmaceuticals's earnings and revenue compare to its market cap? EIGR.Q fundamental statistics Market cap US$12.59m Earnings (TTM ) -US$74.96m Revenue (TTM ) US$15.77m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EIGR.Q income statement (TTM ) Revenue US$15.77m Cost of Revenue US$24.00k Gross Profit US$15.75m Other Expenses US$90.71m Earnings -US$74.96m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -50.62 Gross Margin 99.85% Net Profit Margin -475.26% Debt/Equity Ratio -284.4%
How did EIGR.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/02 16:21 End of Day Share Price 2024/10/01 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Eiger BioPharmaceuticals, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Brian Skorney Baird Madhu Kumar B. Riley Securities, Inc.
Show 8 more analysts 
